NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: ZYDUSLIFE · data 2026-11-01
Zydus Lifesciences Limited
In plain words
Price: at or near its 52-week high.
Delivery: 48.7% of traded shares were kept for delivery over the last 10 sessions, against 51.9% over the last 60.
Latest results: a net profit of ₹940 cr for the quarter ended Jun 2026 (-35.9% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹28,592 cr |
| Net profit (last 12 months) | ₹4,513 cr |
| Sales growth, 3 years (yearly) | 16.6% |
| Profit growth, 3 years (yearly) | 37.0% |
At a glance
Promoters 75.0% (unchanged in a year), pledged 0.0%, institutions 18.3%.
P/E 27.8, dividend yield 0.1%. Price relative to earnings and book value (low is cheaper, not better).
ROE 19.7%, ROCE 17.8%, operating margin 18.6%: how much profit it earns on the money it uses.
Debt/equity 0.46, Profit growth 37.0% and sales growth 16.6% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- High return on equity (19.7%).
- Profit grew 37.0% a year over 3 years.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
ZYDUSLIFE Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹8,017 crore, up 22% YoY and up 5.7% QoQ.
Net profit was ₹939.8 crore, down 35.9% YoY and down 26.1% QoQ.
Operating margin was 24.1% (31.8% a year ago).
EPS was ₹9.35, down 35.9% YoY and down 26.1% QoQ.
ZYDUSLIFE के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹8,017 करोड़; पिछले साल की तुलना में 22% की बढ़त, पिछली तिमाही की तुलना में 5.7% की बढ़त।
शुद्ध मुनाफ़ा: ₹939.8 करोड़; पिछले साल की तुलना में 35.9% की गिरावट, पिछली तिमाही की तुलना में 26.1% की गिरावट।
ऑपरेटिंग मार्जिन: 24.1% (एक साल पहले 31.8%)।
EPS: ₹9.35; पिछले साल की तुलना में 35.9% की गिरावट, पिछली तिमाही की तुलना में 26.1% की गिरावट।
ZYDUSLIFEના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹8,017 કરોડ; ગયા વર્ષની સરખામણીએ 22% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 5.7% વધારો.
ચોખ્ખો નફો: ₹939.8 કરોડ; ગયા વર્ષની સરખામણીએ 35.9% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 26.1% ઘટાડો.
ઓપરેટિંગ માર્જિન: 24.1% (એક વર્ષ પહેલાં 31.8%).
EPS: ₹9.35; ગયા વર્ષની સરખામણીએ 35.9% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 26.1% ઘટાડો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
24/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Delivery 49.3% over the last 20 sessions vs 48.3% in the 40 before (1.02x); shares delivered per day 0.9x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 11/15: 18 schemes hold it, about ₹2,641 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 8/15: Verdict "Building", sustained score 49/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Dividend
- 11 Aug 26Results Q1 FY27 results: profit −35.9% YoY +7.7% next session
- 24 Jul 26Dividend Dividend ₹1 (ex-date) -0.5% next session
- 19 May 26Results Q4 FY26 results: profit +1647.9% YoY +5.0% next session
- 9 Feb 26Results Q3 FY26 results: profit +1.8% YoY -0.1% next session
- 6 Nov 25Results Q2 FY26 results: profit +38.1% YoY -2.8% next session
- 12 Aug 25Results Q1 FY26 results: profit +3.3% YoY +3.5% next session
- 25 Jul 25Dividend Dividend ₹11 (ex-date) +0.9% next session
- 20 May 25Results Q4 FY25 results: profit +14.1% YoY -2.4% next session
- 5 Feb 25Results Q3 FY25 results: profit +29.6% YoY +3.5% next session
- 12 Nov 24Results Q2 FY25 results: profit +13.8% YoY -0.4% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹8,017 cr | ₹940 cr | -35.9% | 24.1% | 9.35 |
| Mar 2026 | ₹7,587 cr | ₹1,273 cr | +1647.9% | 33.7% | 12.65 |
| Dec 2025 | ₹6,865 cr | ₹1,042 cr | +1.8% | 26.5% | 10.36 |
| Sept 2025 | ₹6,123 cr | ₹1,259 cr | +38.1% | 32.9% | 12.51 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 75.01% | 75.01% | 75.00% | 75.00% |
| Foreign institutions (FII) | 7.05% | 6.88% | 6.95% | 7.06% |
| Domestic institutions (DII) | 11.28% | 11.27% | 11.20% | 11.09% |
| Mutual funds | 6.88% | 5.12% | 4.88% | 4.71% |
| Retail investors | 4.56% | 4.71% | 4.80% | 4.78% |
| Number of shareholders | 3,82,067 | 3,99,251 | 4,18,314 | 4,03,266 |
Common questions
What was Zydus Lifesciences Limited's latest quarterly profit?
Zydus Lifesciences Limited reported a net profit of ₹940 cr for the quarter ended Jun 2026 (-35.9% on the same quarter a year earlier), on revenue of ₹8,017 cr.
How much do promoters hold in Zydus Lifesciences Limited?
Promoters held 75.01% of Zydus Lifesciences Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Zydus Lifesciences Limited debt-free?
Its latest reported debt-to-equity ratio is 0.46.
What is Zydus Lifesciences Limited's P/E ratio?
About 27.8, based on the last 12 months' earnings and a price of ₹1,245.5 (data 2026-11-01).
What is the 52-week high and low of Zydus Lifesciences Limited?
The 52-week high is ₹1,248.9 and the 52-week low is ₹835.5.
Mutual funds holding Zydus Lifesciences Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 18 schemes holding about ₹2,641 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| Parag Parikh Flexi Cap Fund | PPFAS Mutual Fund | 1.54% | ₹2,234 cr |
| NIPPON INDIA ETF NIFTY NEXT 50 JUNIOR BEES | Nippon India Mutual Fund | 1.18% | ₹102 cr |
| Parag Parikh ELSS Tax Saver Fund | PPFAS Mutual Fund | 1.75% | ₹95 cr |
| Nippon India Nifty Pharma ETF | Nippon India Mutual Fund | 2.92% | ₹51 cr |
| ADITYA BIRLA SUN LIFE QUANT FUND | Aditya Birla Sun Life Mutual Fund | 2.12% | ₹39 cr |
| SBI Nifty Next 50 ETF | SBI Mutual Fund | 1.18% | ₹34 cr |
| Nippon India Nifty Alpha Low Volatility 30 Index Fund | Nippon India Mutual Fund | 2.79% | ₹33 cr |
| SBI Nifty Next 50 Index Fund | SBI Mutual Fund | 1.19% | ₹28 cr |
| Mirae Asset Nifty Next 50 ETF | Mirae Asset Mutual Fund | 1.18% | ₹17 cr |
| ADITYA BIRLA SUN LIFE NIFTY NEXT 50 INDEX FUND | Aditya Birla Sun Life Mutual Fund | 1.18% | ₹3 cr |
| ADITYA BIRLA SUN LIFE NIFTY HEALTHCARE ETF | Aditya Birla Sun Life Mutual Fund | 2.54% | ₹2 cr |
| Mirae Asset Nifty India Manufacturing ETF | Mirae Asset Mutual Fund | 0.69% | ₹2 cr |
| ADITYA BIRLA SUN LIFE NIFTY NEXT 50 ETF | Aditya Birla Sun Life Mutual Fund | 1.18% | ₹1 cr |
| Mirae Asset Nifty 500 Healthcare ETF | Mirae Asset Mutual Fund | 2.14% | ₹0 cr |
| Nippon India Nifty 500 Low Volatility 50 Index Fund | Nippon India Mutual Fund | 0.97% | ₹0 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Zydus Lifesciences Limited | ₹1,245.5 | ₹1,24,089 cr | 27.8 | — | 19.7% | 17.8% | 0.46 | +24.1% |
| Torrent Pharmaceuticals Ltd | ₹4,613.4 | ₹1,76,300 cr | 75.6 | 9.6 | 27.1% | 13.5% | 1.79 | +28.0% |
| Laurus Labs Ltd. | ₹2,405.5 | ₹1,29,243 cr | 97.1 | 21.5 | 18.2% | 20.5% | 0.48 | +149.8% |
| Dr. Reddy's Laboratories Ltd. | ₹1,352 | ₹1,12,643 cr | 40.3 | 2.9 | 12.1% | 12.1% | 0.21 | +13.0% |
| Mankind Pharma Ltd. | ₹2,492.8 | ₹1,02,797 cr | 46 | 5.9 | 12.5% | 12.7% | 0.39 | +1.4% |
| Glenmark Pharmaceuticals Limited | ₹2,298.7 | ₹65,137 cr | 36.1 | — | 14.1% | 29.2% | 0.06 | +24.1% |
Compare ZYDUSLIFE with TORNTPHARM in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open ZYDUSLIFE in NSE Scanner →